BRIEF—uniQure sells Hemgenix royalty interest for $400 million

Dutch gene therapy company uniQure has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of Hemgenix (etranacogene dezaparvovec-drbl) to HealthCare Royalty (HCRx) and Sagard Healthcare for a gross purchase price of up to $400 million in cash.

uniQure will receive an upfront cash payment of $375 million in exchange for the lowest royalty tier on CSL Behring’s worldwide net sales of Hemgenix up to 1.85 times the purchase price until June 30, 2032 or, if such cap is not met by June 30, 2032, up to 2.25x the purchase price through December 31, 2038.

uniQure also is eligible for an additional $25 million milestone payment if 2024 net sales of Hemgenix exceed a pre-specified threshold. uniQure will retain the rights to all other royalties under its existing Commercialization and license agreement with CSL Behring, as well as contractual milestones totaling up to $1.5 billion,